Device Rotablator_ic

Rotablator Rotational Atherectomy System Console Kit

Payments companies reported to CMS as associated with Rotablator Rotational Atherectomy System Console Kit. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$50Kassociated payments (2023-2025)
632clinicians with associated payments
1company reporting

By year

2023 $19K
2024 $11K
2025 $20K

Payments reported as associated with Rotablator Rotational Atherectomy System Console Kit, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Interventional Cardiology $26K
Cardiovascular Disease $11K
Internal Medicine $3,719
Nurse Practitioner $1,207
Family $938
Hospitalist $729

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Rotablator Rotational Atherectomy System Console Kit

These are the largest totals companies reported as associated with Rotablator Rotational Atherectomy System Console Kit. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Ahmad Khraisat Greenfield, WI Interventional Cardiology $1,184.37
Adam Bykowski Milwaukee, WI Interventional Cardiology $850.90
Paul Mahoney Greenville, NC Interventional Cardiology $514.94
Faisal Masood Milwaukee, WI Internal Medicine $512.93
Youssef Garcia-Bengochea Athens, GA Cardiovascular Disease $490.40
Mina Iskander Milwaukee, WI Interventional Cardiology $472.25
Iyad Azzam Milwaukee, WI Interventional Cardiology $437.67
Hani Hashim Sheboygan, WI Interventional Cardiology $399.45
Qais Radaideh Omaha, NE Cardiovascular Disease $399.39
Babak Haddadian Milwaukee, WI Interventional Cardiology $395.64

Prescribed Rotablator Rotational Atherectomy System Console Kit?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.